European regulators have rejected Pfizer Inc.’s tanezumab, casting further doubts on whether the FDA will okay the troubled drug that is intended as a non-opioid alternative for osteoarthritis pain.

Replicate Bioscience Inc. secured a $40 million series A round to take a portfolio of preclinical projects employing self-replicating RNA into the clinic.